GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » EV-to-EBIT

Panacea Acquisition II (Panacea Acquisition II) EV-to-EBIT : -247.21 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Panacea Acquisition II's Enterprise Value is $241.03 Mil. Panacea Acquisition II's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98 Mil. Therefore, Panacea Acquisition II's EV-to-EBIT for today is -247.21.

The historical rank and industry rank for Panacea Acquisition II's EV-to-EBIT or its related term are showing as below:

PANA's EV-to-EBIT is not ranked *
in the Diversified Financial Services industry.
Industry Median: 9.71
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Panacea Acquisition II's Enterprise Value for the quarter that ended in Dec. 2022 was $236.56 Mil. Panacea Acquisition II's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98 Mil. Panacea Acquisition II's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -0.41%.


Panacea Acquisition II EV-to-EBIT Historical Data

The historical data trend for Panacea Acquisition II's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II EV-to-EBIT Chart

Panacea Acquisition II Annual Data
Trend Dec21 Dec22
EV-to-EBIT
- -242.62

Panacea Acquisition II Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EV-to-EBIT Get a 7-Day Free Trial - -305.30 -304.19 -305.89 -242.62

Competitive Comparison of Panacea Acquisition II's EV-to-EBIT

For the Shell Companies subindustry, Panacea Acquisition II's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Acquisition II's EV-to-EBIT Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's EV-to-EBIT falls into.



Panacea Acquisition II EV-to-EBIT Calculation

Panacea Acquisition II's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=241.031/-0.975
=-247.21

Panacea Acquisition II's current Enterprise Value is $241.03 Mil.
Panacea Acquisition II's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II  (NAS:PANA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Panacea Acquisition II's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 ) =EBIT / Enterprise Value (Q: Dec. 2022 )
=-0.975/236.55725
=-0.41 %

Panacea Acquisition II's Enterprise Value for the quarter that ended in Dec. 2022 was $236.56 Mil.
Panacea Acquisition II's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Acquisition II (Panacea Acquisition II) Business Description

Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines